Isa-VRd in transplant-ineligible patients with newly diagnosed multiple myeloma and high-risk features

In the phase III BENEFIT study the combination of Isatuximab with bortezomib-, lenalidomide and dexamethasone (Isa-VRd) was shown to significantly increase the 18-month MRD negativity rate compared to Isa-Rd in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). During ASH 2024, Prof Xavier Leleu (Hôpital La Mileterie, CHU Poitiers, Poitiers, France) presented updated results of this trial looking at the efficacy results in function of the risk profile of patients. Interestingly, the clinical benefit obtained with Isa-VRd over Isa-Rd proved to be more pronounced in the subgroup of patients with high-risk disease according to the new IMS HR definition than in patients with non-high risk disease.